J0896 Luspatercept - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Luspatercept

Brand Name:

Reblozyl

Strength:

0.25mg

HCPCS:

J0896

SEER*Rx Category:

Ancillary Therapy

Major Drug Class:

Erythropoiesis-Stimulating Agent

Minor Drug Class:

Oral (Y/N):

No

FDA Approval Year:

2019

FDA Discontinuation Year:

CMS Effective Date:

July 1, 2020

CMS Discontinuation Date:

Status:

In Use